Form 4: Arcturus Therapeutics CFO Andy Sassine Acquires 60,000 Stock Options

Arcturus Therapeutics' Chief Financial Officer, Andy Sassine, was granted 60,000 stock options on December 16, 2024, according to a recent SEC filing.

Summary

• Andy Sassine, the Chief Financial Officer of Arcturus Therapeutics Holdings Inc., was granted 60,000 employee stock options on December 16, 2024.
• The options have an exercise price of $16.24 per share.
• These options vest 25% on December 16, 2025, and the remaining 75% vest in equal monthly increments over the following 36 months.
• The options expire on December 16, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There is no indication of any negative sentiment.

Positives

• The grant of stock options aligns the CFO's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Industry Context

Stock option grants are a common form of compensation for executives in the biotechnology industry, aligning their interests with the long-term performance of the company.

Comparison to Industry Standards

• Stock option grants are a standard practice in the biotech industry to incentivize executives.
• The vesting schedule of 25% after one year and the remainder over the following 36 months is a typical vesting schedule for stock options.
• The exercise price of $16.24 is specific to Arcturus Therapeutics and would need to be compared to the current market price of the stock to assess its value.

Stakeholder Impact

• The stock option grant may positively impact shareholder confidence by aligning management's interests with the company's long-term success.
• The grant of options may motivate the CFO to work towards increasing the company's value.

Key Dates

Keywords

stock options, insider trading, SEC Form 4, Arcturus Therapeutics, equity compensation, Andy Sassine, CFO